STARTUP PROFILE

Ampa Health

COUNTRY
USA
FOUNDED
2022
CATEGORY
Neuromodulation
Developing a portable transcranial magnetic stimulation system to expand access to clinically validated neuromodulation treatments for mental health disorders.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Seed
MODALITY
TMS
FORM FACTOR
External device
INTERFACE DEPTH
Non-invasive
INDICATION
Psychiatry
TARGET USER
Patients
REGULATORY STAGE
FDA cleared (510k)
Ampa Health is positioned around expanding TMS access by miniaturizing the delivery system into a portable form factor, addressing the key bottleneck of clinic-bound infrastructure that limits current TMS adoption. With FDA clearance and seed-stage funding, it sits at an early commercial stage in a TMS market otherwise dominated by large-footprint systems from BrainsWay and Magstim.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
13
Neurotech wants to challenge GLP-1s
27 October – 10 November 2026

Wave Neuroscience and Ampa will bring Wave’s EEG-guided MeRT protocols to the portable Ampa One TMS system. Clinics that license MeRT can now run it on Ampa units they already have.

#
12
NVIDIA and OpenAI invest in neurotech
13 October – 27 October 2026

Ampa launched Target Lock for its portable Ampa One TMS system. The new feature uses an embedded camera and neuronavigation cap to monitor coil positioning during treatment. If the coil moves off target, stimulation automatically pauses until it is realigned.

Articles featuring
Ampa Health